OPKO Health Inc. (OPK) News
Filter OPK News Items
OPK News Results
|Loading, please wait...|
OPK News Highlights
- OPK's 30 day story count now stands at 4.
- Over the past 28 days, the trend for OPK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TALK are the most mentioned tickers in articles about OPK.
Latest OPK News From Around the Web
Below are the latest news stories about OPKO HEALTH INC that investors may wish to consider to help them evaluate OPK as an investment opportunity.
Quite a few insiders have dramatically grown their holdings in OPKO Health, Inc. ( NASDAQ:OPK ) over the past 12...
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Shareholders Approve All Measures at First Annual Meeting of StockholdersNEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (Nasdaq: TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company’s board of directors and approved all other shareholder proposals during the company’s first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Healt
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...
In this article, we will be taking a look at the top 10 stocks to buy according to Roger Ibbotson’s Zebra Capital. To skip our detailed analysis, you can go directly to see 5 Stocks to Buy According to Roger Ibbotson’s Zebra Capital. Ibbotson’s top 10 stock picks lost 9.5% since the end of the first […]
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.
MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO. He will remain as an employed advisor to the company through the end of December 2022 and continue as a consultant for the following nine months to assist in positioning t
Counterintuitively, week-to-date, as of Thursday afternoon, Opko stock was up by almost 10%, according to S&P Global Market Intelligence. There was no ambiguity -- Opko fell notably short of expectations for the period. Opko's steep drop in the diagnostics segment (53% year over year to just under $187 million) was worse than many projected, but it wasn't a shock.
The analysts covering OPKO Health, Inc. ( NASDAQ:OPK ) delivered a dose of negativity to shareholders today, by making...
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.